tetano
Editor, Senior Moderator
Front Immunol
. 2021 Dec 23;12:786554.
doi: 10.3389/fimmu.2021.786554. eCollection 2021.
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
Qiu-Yan Xu[SUP] 1 2 [/SUP], Jian-Hang Xue[SUP] 3 [/SUP], Yao Xiao[SUP] 1 4 [/SUP], Zhi-Juan Jia[SUP] 5 [/SUP], Meng-Juan Wu[SUP] 5 [/SUP], Yan-Yun Liu[SUP] 5 [/SUP], Wei-Li Li[SUP] 6 [/SUP], Xian-Ming Liang[SUP] 1 [/SUP], Tian-Ci Yang[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: A vaccine against coronavirus disease 2019 (COVID-19) with highly effective protection is urgently needed. The anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and duration after vaccination are crucial predictive indicators.
Objectives: To evaluate the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies after vaccination and their predictive value for protection.
Methods: We determined the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies (neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA) in 61 volunteers within 160 days after the CoronaVac vaccine. A logistic regression model was used to determine the predictors of the persistence of neutralizing antibody persistence.
Results: The seropositivity rates of neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA were only 4.92%, 27.87%, 21.31%, 3.28% and 0.00%, respectively, at the end of the first dose (28 days). After the second dose, the seropositivity rates reached peaks of 95.08%, 100.00%, 100.00%, 59.02% and 31.15% in two weeks (42 days). Their decay was obvious and the seropositivity rate remained at 19.67%, 54.10%, 50.82%, 3.28% and 0.00% on day 160, respectively. The level of neutralizing antibody reached a peak of 149.40 (101.00-244.60) IU/mL two weeks after the second dose (42 days) and dropped to 14.23 (7.62-30.73) IU/mL at 160 days, with a half-life of 35.61(95% CI, 32.68 to 39.12) days. Younger participants (≤31 years) had 6.179 times more persistent neutralizing antibodies than older participants (>31 years) (P<0.05). Participants with anti-Spike IgA seropositivity had 4.314 times greater persistence of neutralizing antibodies than participants without anti-Spike IgA seroconversion (P<0.05).
Conclusions: Antibody response for the CoronaVac vaccine was intense and comprehensive with 95.08% neutralizing seropositivity rate, while decay was also obvious after 160 days. Therefore, booster doses should be considered in the vaccine strategies.
Keywords: COVID-19; CoronaVac; SARS-CoV-2; anti-SARS-CoV-2 antibody; neutralizing antibody.
. 2021 Dec 23;12:786554.
doi: 10.3389/fimmu.2021.786554. eCollection 2021.
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
Qiu-Yan Xu[SUP] 1 2 [/SUP], Jian-Hang Xue[SUP] 3 [/SUP], Yao Xiao[SUP] 1 4 [/SUP], Zhi-Juan Jia[SUP] 5 [/SUP], Meng-Juan Wu[SUP] 5 [/SUP], Yan-Yun Liu[SUP] 5 [/SUP], Wei-Li Li[SUP] 6 [/SUP], Xian-Ming Liang[SUP] 1 [/SUP], Tian-Ci Yang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35003104
- PMCID: PMC8733590
- DOI: 10.3389/fimmu.2021.786554
Abstract
Background: A vaccine against coronavirus disease 2019 (COVID-19) with highly effective protection is urgently needed. The anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and duration after vaccination are crucial predictive indicators.
Objectives: To evaluate the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies after vaccination and their predictive value for protection.
Methods: We determined the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies (neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA) in 61 volunteers within 160 days after the CoronaVac vaccine. A logistic regression model was used to determine the predictors of the persistence of neutralizing antibody persistence.
Results: The seropositivity rates of neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA were only 4.92%, 27.87%, 21.31%, 3.28% and 0.00%, respectively, at the end of the first dose (28 days). After the second dose, the seropositivity rates reached peaks of 95.08%, 100.00%, 100.00%, 59.02% and 31.15% in two weeks (42 days). Their decay was obvious and the seropositivity rate remained at 19.67%, 54.10%, 50.82%, 3.28% and 0.00% on day 160, respectively. The level of neutralizing antibody reached a peak of 149.40 (101.00-244.60) IU/mL two weeks after the second dose (42 days) and dropped to 14.23 (7.62-30.73) IU/mL at 160 days, with a half-life of 35.61(95% CI, 32.68 to 39.12) days. Younger participants (≤31 years) had 6.179 times more persistent neutralizing antibodies than older participants (>31 years) (P<0.05). Participants with anti-Spike IgA seropositivity had 4.314 times greater persistence of neutralizing antibodies than participants without anti-Spike IgA seroconversion (P<0.05).
Conclusions: Antibody response for the CoronaVac vaccine was intense and comprehensive with 95.08% neutralizing seropositivity rate, while decay was also obvious after 160 days. Therefore, booster doses should be considered in the vaccine strategies.
Keywords: COVID-19; CoronaVac; SARS-CoV-2; anti-SARS-CoV-2 antibody; neutralizing antibody.